Striverdi Respimat Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A timeline chronicling the development of Boehringer Ingelheim’s chronic obstructive pulmonary disease treatment olodaterol.
You may also be interested in...
Manufacturing Updates in Brief
GMP issues delayed Boehringer launch; Nigerian firms meet WHO GMPs; Novartis closing Puerto Rico plant; Hospira closing Clayton site; Valeant looks to move Bausch + Lomb manufacturing abroad; these IV bags were training aides.
Manufacturing Updates in Brief
GMP issues delayed Boehringer launch; Nigerian firms meet WHO GMPs; Novartis closing Puerto Rico plant; Hospira closing Clayton site; Valeant looks to move Bausch + Lomb manufacturing abroad; these IV bags were training aides.
Striverdi Respimat Reviewers
FDA staff that participated in the review of Boehringer Ingelheim’s olodaterol for chronic obstructive pulmonary disease.